Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma (HOPE)
Primary Purpose
Cholangiocarcinoma, Interventional Imaging
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Irreversible electroporation
Sponsored by
About this trial
This is an interventional treatment trial for Cholangiocarcinoma focused on measuring Cholangiocarcinoma, Irreversible electroporation, Interventional radiology
Eligibility Criteria
Inclusion Criteria:
- 18-75 years old
- Patient with infiltrating cholangiocarcinoma of the gallstone convergence considered as unresectable on the pre-operative imaging data performed during the month preceding inclusion, and in multidisciplinary consultation meeting specialised in digestive oncology
- Histologically (or cytologically) proven tumor of less than 4 cm of the largest diameter
- World Health Organization Performance Index 0 or 1
- No history of other cancer, except baso-cellular skin carcinoma or epidermoid cervix cancer or any other cancer in complete remission for more than 3 years
- No prior radiotherapy for cholangiocarcinoma
- Biological analyses performed during the month preceding inclusion : hepatic enzymes (AST and ALT <3N), preserved renal function (creatinine clearance according to Modification of the Diet in Renal Disease >50ml/min); bilirubin <3N; bile drainage must be correct with a bilirubin below 3N , with or without drainage/prothesis, hemoglobin >9g/dL, leucocytes >3500/mm3, platelets >75000/mm3, prothrombin rate >70%
- Signature of the informed consent
Exclusion Criteria:
- Cholangiocarcinoma of more than 4cm diameter or resectable according tio the imaging data
- Severe and/or uncontrolled (cardiac, pulmonary, renal, liver decompensation...) visceral failure, in the 6 months preceding the study
- Visceral metastases or peritoneal carcinosis
- History of cancers except if remission for more than 3 years, in-situ cancer, epidermoid or baso-cellular cancer
- Metal biliary prothesis non extractable
- Patient with history of epileptic events
- History of myocard infarction for less than 6 months
- Unstabilised coronary disease for at least 6 months
- Cardiac rhythm trouble or QT space above 550ms without treatment
- Patient eligible to liver transplant
- Patient naive of chemiotherapy
- Patient with a pacemaker, an implanted automatic defibrillator or an automatic electronic device or an electronic device with metal pieces
- Patient with contra-indication to the use of NanoKnife system
- History of hypersensitivity to gadolinium or to iodized contrast product not allowing a suitable radiologic monitoring
- Refusal or language or psychic incapacity to sign the informed consent
- Subject who cannot submit to the constraints of the protocol (subjects for which an MRI or a scan is contra-indicated, claustrophobic subjects, non cooperative or not able to come to the follow-up visits)
- Concomitant participation to another study
- Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.
- Women at age to procreate and not using effective contraception
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Electrodes
Arm Description
Electrodes
Outcomes
Primary Outcome Measures
The success rate of the technique, being the realisation of the irreversible electroporation.
The study will be considered positive if the success rate is above 90% and the complication rate below or equal to 30%
Secondary Outcome Measures
Full Information
NCT ID
NCT04717687
First Posted
January 18, 2021
Last Updated
July 11, 2022
Sponsor
Poitiers University Hospital
Collaborators
Sport & Collection 2019
1. Study Identification
Unique Protocol Identification Number
NCT04717687
Brief Title
Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma
Acronym
HOPE
Official Title
Étude Pilote de l'évaluation de la Technique de l'électroporation irréversible Dans le Cholangiocarcinome Infiltrant périhilaire
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Withdrawn
Why Stopped
No enrollment
Study Start Date
May 1, 2021 (Actual)
Primary Completion Date
June 1, 2022 (Actual)
Study Completion Date
June 1, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Poitiers University Hospital
Collaborators
Sport & Collection 2019
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the study is to evaluate the feasibility of irreversible electroporation in the treatment of locally advanced cholangiocarcinoma. This technique would allow to treat the unresectable part of the tumor to make it more accessible for a secondary surgery.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cholangiocarcinoma, Interventional Imaging
Keywords
Cholangiocarcinoma, Irreversible electroporation, Interventional radiology
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Electrodes
Arm Type
Experimental
Arm Description
Electrodes
Intervention Type
Procedure
Intervention Name(s)
Irreversible electroporation
Intervention Description
Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
Primary Outcome Measure Information:
Title
The success rate of the technique, being the realisation of the irreversible electroporation.
Description
The study will be considered positive if the success rate is above 90% and the complication rate below or equal to 30%
Time Frame
At Day 0
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18-75 years old
Patient with infiltrating cholangiocarcinoma of the gallstone convergence considered as unresectable on the pre-operative imaging data performed during the month preceding inclusion, and in multidisciplinary consultation meeting specialised in digestive oncology
Histologically (or cytologically) proven tumor of less than 4 cm of the largest diameter
World Health Organization Performance Index 0 or 1
No history of other cancer, except baso-cellular skin carcinoma or epidermoid cervix cancer or any other cancer in complete remission for more than 3 years
No prior radiotherapy for cholangiocarcinoma
Biological analyses performed during the month preceding inclusion : hepatic enzymes (AST and ALT <3N), preserved renal function (creatinine clearance according to Modification of the Diet in Renal Disease >50ml/min); bilirubin <3N; bile drainage must be correct with a bilirubin below 3N , with or without drainage/prothesis, hemoglobin >9g/dL, leucocytes >3500/mm3, platelets >75000/mm3, prothrombin rate >70%
Signature of the informed consent
Exclusion Criteria:
Cholangiocarcinoma of more than 4cm diameter or resectable according tio the imaging data
Severe and/or uncontrolled (cardiac, pulmonary, renal, liver decompensation...) visceral failure, in the 6 months preceding the study
Visceral metastases or peritoneal carcinosis
History of cancers except if remission for more than 3 years, in-situ cancer, epidermoid or baso-cellular cancer
Metal biliary prothesis non extractable
Patient with history of epileptic events
History of myocard infarction for less than 6 months
Unstabilised coronary disease for at least 6 months
Cardiac rhythm trouble or QT space above 550ms without treatment
Patient eligible to liver transplant
Patient naive of chemiotherapy
Patient with a pacemaker, an implanted automatic defibrillator or an automatic electronic device or an electronic device with metal pieces
Patient with contra-indication to the use of NanoKnife system
History of hypersensitivity to gadolinium or to iodized contrast product not allowing a suitable radiologic monitoring
Refusal or language or psychic incapacity to sign the informed consent
Subject who cannot submit to the constraints of the protocol (subjects for which an MRI or a scan is contra-indicated, claustrophobic subjects, non cooperative or not able to come to the follow-up visits)
Concomitant participation to another study
Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.
Women at age to procreate and not using effective contraception
12. IPD Sharing Statement
Learn more about this trial
Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma
We'll reach out to this number within 24 hrs